1 citations
,
December 2024 in “Archives of Iranian Medicine” Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
November 2015 in “Clin-Alert” Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
3 citations
,
July 2025 in “International Immunopharmacology” A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
29 citations
,
February 2016 in “International Journal of Dermatology” People with lichen planus are more likely to have dyslipidemia, especially higher triglyceride levels.
14 citations
,
January 2017 in “Skin appendage disorders” Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.
February 2024 in “Australasian journal of dermatology” Janus kinase inhibitors may help treat lichen planopilaris.
February 2026 in “Indian Dermatology Online Journal” Tofacitinib significantly improved skin and hair conditions without side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
October 2008 in “Clin-alert” Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.
16 citations
,
October 2014 in “Journal of the American Academy of Dermatology” Oral retinoids may help some patients with hard-to-treat lichen planopilaris, but more research is needed.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
August 2025 in “Journal of the American Academy of Dermatology”
3 citations
,
May 2021 in “Molecules” Rosuvastatin improves lipid levels, reduces inflammation, but worsens insulin sensitivity in men with early-onset hair loss.
22 citations
,
June 2005 in “Clinical Oncology” Orlistat might block the body's ability to absorb thyroid medication.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
June 2019 in “The Egyptian Journal of Fertility and Sterility” Chromium picolinate was better tolerated than metformin for PCOS with fewer side effects.
26 citations
,
January 2016 in “Indian journal of endocrinology and metabolism” Both metformin and pioglitazone improve PCOS symptoms, but pioglitazone is a good alternative for those who can't take metformin.
1 citations
,
August 2022 in “JAAD case reports” Pioglitazone use was linked to hair regrowth in a patient with permanent hair loss from cicatricial alopecia.
May 2024 in “Reactions weekly”
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
6 citations
,
December 2020 in “Biological & Pharmaceutical Bulletin” Compounds from Eclipta prostrata L. plant have diabetes and obesity-fighting properties and reduce inflammation.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
3 citations
,
July 2025 in “Obesity Facts” GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin in reducing type 2 diabetes risk in women with PCOS.
1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
2 citations
,
June 2009 in “PubMed”